

## December 2024 EBD Formulary Recommendations

Drug Name	Date Drug Considered by EBD	Use	Current Setup	EBD Recommendation (based on input from EBRx and Navitus)	Impacted Members	Cost Details	Commission Decision	Board of Finance Decision
tolterodine SR cap	12/5/24	Overactive bladder	Tier 2	<b>Tier 1</b>	93	~\$1.00 per capsule	Approve Recommendation	Approve Recommendation
fesoterodine fumarate ER tab	12/5/24	Overactive bladder	Tier 2	<b>Tier 1</b>	12	~\$1.30 per tablet	Approve Recommendation	Approve Recommendation
CERDELGA CAP	12/5/24	Gaucher disease	S, SP, PA	<b>S, SP, PA, QL= 2 caps/day</b>	2 0 affected by new QL	\$563.48 per capsule	Approve Recommendation	Approve Recommendation
miglustat cap	12/5/24	Gaucher disease	Tier 1, SP, PA	<b>Tier 1, SP, PA, QL= 3 caps/day</b>	0	\$267.90 per capsule	Approve Recommendation	Approve Recommendation
Voydeya (danicopan)	12/5/24	Paroxysmal nocturnal hemoglobinuria (PNH)	New Drug (NC)	<b>Tier 4, SP, PA, QL=6 tabs/day</b>	0	\$4,957 per 30 days	Approve Recommendation	Approve Recommendation
Xolremdi (mavoxifafor)	12/5/24	WHIM syndrome	New Drug (NC)	<b>EXCLUDE</b>	0	\$30,600 - \$40,800 / 30 days	Approve Recommendation	Approve Recommendation
Ojemda (tovorafenib) suspension	12/5/24	BRAF-mutated glioma	New Drug (NC)	<b>EXCLUDE</b>	0	Suspension: \$14,000 - \$68,000 / 30 days depending on affected body surface area	Approve Recommendation	Approve Recommendation
Ojemda (tovorafenib) tablets	12/5/24	BRAF-mutated glioma	New Drug (NC)	<b>EXCLUDE</b>	0	Tablets: \$34,000 / 28 days	Approve Recommendation	Approve Recommendation
Winrevair (sotatercept)	12/5/24	Pulmonary Arterial Hypertension Group I (PAH)	New Drug (NC)	<b>EXCLUDE</b>	0	\$20,000 / 30 days (adjusted)  If > 85 kg ~\$40,000 / 30 days (adjusted)	Approve Recommendation	Approve Recommendation

Drug Name	Date Drug Considered by EBD	Use	Current Setup	EBD Recommendation (based on input from EBRx and Navitus)	Impacted Members	Cost Details	Commission Decision	Board of Finance Decision
Duvyzat (givinostat)	12/5/24	Duchenne Muscular Dystrophy (DMD)	New Drug (NC)	<b>EXCLUDE</b>	0	~ \$74,000 / 30 days	Approve Recommendation	Approve Recommendation
Lazcluze (lazertinib) – (combo w/ Rybrevant IV)	12/5/24	EGFR-mutated Non-small Cell Lung Cancer (NSCLC)	New Drug (NC)	<b>EXCLUDE</b>	0	\$18,198 / 30 days	Approve Recommendation	Approve Recommendation